BioNTech has generated tens of billions of euros through its successful COVID-19 vaccine rollout with partner Pfizer. (Photo by Sean Gallup/Getty Images) Even as Germany's BioNTech deals with ongoing ...

The deal comes as BioNTech works to complete the $1.25 billion acquisition of CureVac that it announced in June. (Avosb/iStock/Getty Images Plus) The chapter on Pfizer and BioNTech’s mRNA patent feud ...

BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other claims ...

I rate BioNTech SE a hold due to volatile financial performance, weak growth, and premium valuation. The company's financials are heavily reliant on COVID-19 vaccines, with declining demand impacting ...

The U.S. is poised to get its first vaccine for Covid-19. An independent advisory panel to the U.S. Food and Drug Administration voted Thursday in favor of the vaccine developed by Pfizer and BioNTech ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A broad rally in vaccine stocks has put BioNTech on track for its best day in six years. That momentum may not last. Shares of the German biotech surged 20% to $111.27 on Wednesday, pacing toward ...

Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...

The extremely creepy Santa-died-from-COVID “John Snow Project” video has left many both puzzled and outraged. David Bell, for instance, described it in a tweet as “Using Christmas to promote ...